Evolution of prognostic factors in hepatocellular carcinoma in Japan

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 3, 2010, Pages 407-414

  Nouso, K ^a   Kobayashi, Y ^a   Nakamura, S ^a   Kobayashi, S ^a   Toshimori, J ^a   Kuwaki, K ^a   Hagihara, H ^a   Onishi, H ^a   Miyake, Y ^a   Ikeda, F ^a   Shiraha, H ^a   Takaki, A ^a   Iwasaki, Y ^a   Kobashi, H ^a   Yamamoto, K ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY;

ADULT; AGED; ARTICLE; ASCITES; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; JAPAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CANCER; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION; RISK FACTOR; TUMOR VOLUME;

AGED; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS C ANTIBODIES; HUMANS; JAPAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 73549095772     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04179.x     Document Type: Article

References (26)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001 2 : 533 543.
2. Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol 2003 39 : 1076 1084.
3. Adams PC, Arthur MJ, Boyer TD, et al. Screening in liver disease: report of an AASLD clinical workshop. Hepatology 2004 39 : 1204 1212.
4. Trevisani F, Cantarini MC, Labate AM, et al. Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. Am J Gastroenterol 2004 99 : 1470 1476.
5. Ikai I, Arii S, Kojiro M, et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 2004 101 : 796 802.
6. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001 35 : 421 430.
7. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005 40 : 225 235.
8. Makuuchi M, Kokudo N. Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. World J Gastroenterol 2006 12 : 828 829.
9. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999 131 : 174 181.
10. Kudo M. Impact of interferon therapy after curative treatment of hepatocellular carcinoma. Oncology 2008 75 (Suppl 1 30 41.
11. Liaw YF. Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma. Semin Liver Dis 2005 25 (Suppl 1 40 7.
12. Matsumoto A, Tanaka E, Rokuhara A, et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res 2005 32 : 173 184.
13. Piao CY, Fujioka S, Iwasaki Y, et al. Lamivudine treatment in patients with HBV-related hepatocellular carcinoma - using an untreated, matched control cohort. Acta Med Okayama 2005 59 : 217 224.
14. Honda H, Ochiai K, Adachi E, et al. Hepatocellular carcinoma: correlation of CT, angiographic, and histopathologic findings. Radiology 1993 189 : 857 862.
15. Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer 2007 43 : 979 992.
16. Sala M, Forner A, Varela M, Bruix J. Prognostic prediction in patients with hepatocellular carcinoma. Semin Liver Dis 2005 25 : 171 180.
17. Varela M, Sala M, Llovet JM, Bruix J. Review article: natural history and prognostic prediction of patients with hepatocellular carcinoma. Aliment Pharmacol Ther 2003 17 (Suppl 2 98 102.
18. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007 132 : 2557 2576.
19. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004 130 : 417 422.
20. Tanaka H, Nouso K, Kobashi H, et al. Surveillance of hepatocellular carcinoma in patients with hepatitis C virus infection may improve patient survival. Liver Int 2006 26 : 543 551.
21. Chen CJ, Yang HI, Iloeje UH, REVEAL-HBV Study Group. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009 49 : S72 84.
22. Shiratori Y, Shiina S, Teratani T, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003 138 : 299 306.
23. Shiratori Y, Kato N, Yokosuka O, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology 1997 113 : 558 566.
24. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998 352 : 1426 1432.
25. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 965.
26. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 982.